Compare MTX & AAPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MTX | AAPG |
|---|---|---|
| Founded | 1968 | 2009 |
| Country | United States | China |
| Employees | N/A | 767 |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.0B |
| IPO Year | 2004 | N/A |
| Metric | MTX | AAPG |
|---|---|---|
| Price | $78.67 | $17.12 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $82.00 | $48.40 |
| AVG Volume (30 Days) | ★ 121.4K | 8.2K |
| Earning Date | 04-30-2026 | 05-20-2026 |
| Dividend Yield | ★ 0.68% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.17 | N/A |
| Revenue | ★ $2,072,600,000.00 | N/A |
| Revenue This Year | $5.66 | $290.34 |
| Revenue Next Year | $4.47 | N/A |
| P/E Ratio | $66.47 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $53.94 | $16.92 |
| 52 Week High | $84.34 | $48.45 |
| Indicator | MTX | AAPG |
|---|---|---|
| Relative Strength Index (RSI) | 57.21 | 34.13 |
| Support Level | $74.20 | $16.92 |
| Resistance Level | $84.34 | $25.23 |
| Average True Range (ATR) | 1.91 | 0.57 |
| MACD | 0.07 | 0.04 |
| Stochastic Oscillator | 76.61 | 5.67 |
Minerals Technologies Inc mines, produces, and sells mineral-based products. The firm organizes itself into two segments: The Consumer & Specialties segment that derives maximum revenue, serves consumer end markets directly with mineral-to-market finished products and also provides specialty mineral-based solutions and technologies that are an essential component of its customers' finished products; and The Engineered Solutions segment serves industrial end markets with engineered systems, mineral blends, and technologies that are designed to improve its customers' manufacturing processes and projects. The majority of revenue comes from the United States, while it also has its presence in Canada/Latin America, Europe/Africa, and Asia.
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies and currently has seven drug candidates in pipeline under research. The company's geographical segments include the United States and Mainland China.